<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-84612</identifier>
<setSpec>1699-258X</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Anti-TNF-alpha therapy in ankylosing spondylitis: symptom control and structural damage modification</dc:title>
<dc:description xml:lang="en">Anti-TNFalpha agents represent an outstanding advance in the symptomatic control of patients with ankylosing spondylitis presenting an inadequate response to non-steroidal anti-inflammatory drugs. Anti-TNFalpha antagonists have demonstrated efficacy and safety in the long-term but continuous therapy is needed for an adequate control of symptoms. After the failure to a first anti-TNFalpha agent, the use of a second TNFalpha antagonist seems to be effective and safe. Despite the fast and continuous suppression of bone inflammation, demonstrated by magnetic resonance imaging, the beneficial effect of treatment with TNFalpha antagonists on the radiological evolution has not been demonstrated to date in ankylosing spondylitis. It seems that insights into new therapeutic molecular targets implicated in the process of ossification are needed(AU)</dc:description>
<dc:creator>Otón, Teresa</dc:creator>
<dc:creator>Sanz, Jesús</dc:creator>
<dc:creator>Andreu, José Luis</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Los agentes anti-TNFalfa han representado un notable avance en el control sintomático de los pacientes con espondilitis anquilosante y respuesta inadecuada a AINE. Los antagonistas del TNFalfa son eficaces y seguros a largo plazo pero es necesario su uso continuado para un adecuado control sintomático. Tras el fracaso a uno de ellos, el uso de un segundo agente anti-TNFalfa parece ser eficaz y seguro. Aun no se ha demostrado un efecto beneficioso del tratamiento con antagonistas del TNFalfa sobre la evolución radiológica en la espondilitis anquilosante, a pesar de la desaparición rápida y mantenida de la inflamación ósea, evidenciada mediante RM. Parece necesario explorar nuevas dianas moleculares implicadas en el proceso de osificación(AU)</dc:description>
<dc:source>Reumatol. clín. (Barc.);7(1): 51-55, ene.-feb.2011. tab, ilus</dc:source>
<dc:identifier>ibc-84612</dc:identifier>
<dc:title xml:lang="es">Terapia anti-TNFalfa en espondilitis anquilosante: control sintomático y modificación del daño estructural</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d13552^s29166</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d29591^s22073</dc:subject>
<dc:subject>^d13552^s22032</dc:subject>
<dc:subject>^d34460^s22073</dc:subject>
<dc:subject>^d31092^s22007</dc:subject>
<dc:subject>^d29591^s22078</dc:subject>
<dc:subject>^d13552^s22067</dc:subject>
<dc:subject>^d13552^s22057</dc:subject>
<dc:subject>^d29591^s22000</dc:subject>
<dc:subject>^d31092^s22038</dc:subject>
<dc:type>article</dc:type>
<dc:date>201102</dc:date>
</metadata>
</record>
</ibecs-document>
